Literature DB >> 34105031

Insight into the sequence-specific elements leading to increased DNA bending and ligase-mediated circularization propensity by antitumor trabectedin.

Alberto Mills1, Federico Gago2.   

Abstract

DNA curvature is the result of a combination of both intrinsic features of the double helix and external distortions introduced by the environment and the binding of proteins or drugs. The propensity of certain double-stranded DNA (dsDNA) sequences to bend is essential in crucial biological processes, such as replication and transcription, in which proteins are known to either recognize noncanonical DNA conformations or promote their formation upon DNA binding. Trabectedin (Yondelis®) is a clinically used antitumor drug which, following covalent bond formation with the 2-amino group of guanine, induces DNA curvature and enhances the circularization ratio, upon DNA ligation, of several dsDNA constructs but not others. By means of unrestrained molecular dynamics simulations using explicitly solvated all-atom models, we rationalize these experimental findings in structural terms and shed light on the crucial, albeit possibly underappreciated, role played by T4 DNA ligase in stabilizing a bent DNA conformation prior to cyclization. Taken together, our results expand our current understanding on how DNA shape modification by trabectedin may affect both the sequence-specific recognition by transcription factors to promoter sites and RNA polymerase II binding.

Entities:  

Keywords:  DNA structure; DNA-binding drugs; Molecular dynamics

Mesh:

Substances:

Year:  2021        PMID: 34105031     DOI: 10.1007/s10822-021-00396-4

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  36 in total

1.  Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Authors:  M Zewail-Foote; L H Hurley
Journal:  J Med Chem       Date:  1999-07-15       Impact factor: 7.446

Review 2.  Unique features of trabectedin mechanism of action.

Authors:  Annette K Larsen; Carlos M Galmarini; Maurizio D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-14       Impact factor: 3.333

3.  Mode of action of trabectedin in myxoid liposarcomas.

Authors:  S Di Giandomenico; R Frapolli; E Bello; S Uboldi; S A Licandro; S Marchini; L Beltrame; S Brich; V Mauro; E Tamborini; S Pilotti; P G Casali; F Grosso; R Sanfilippo; A Gronchi; R Mantovani; R Gatta; C M Galmarini; J M F Sousa-Faro; M D'Incalci
Journal:  Oncogene       Date:  2013-11-11       Impact factor: 9.867

4.  XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

Authors:  Sascha Feuerhahn; Christophe Giraudon; Marta Martínez-Díez; Juan A Bueren-Calabuig; Carlos M Galmarini; Federico Gago; Jean-Marc Egly
Journal:  Chem Biol       Date:  2011-08-26

5.  Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B.

Authors:  C Cuevas; M Pérez; M J Martín; J L Chicharro; C Fernández-Rivas; M Flores; A Francesch; P Gallego; M Zarzuelo; F de La Calle; J García; C Polanco; I Rodríguez; I Manzanares
Journal:  Org Lett       Date:  2000-08-10       Impact factor: 6.005

6.  DNA bending is a determinant of calicheamicin target recognition.

Authors:  A A Salzberg; P C Dedon
Journal:  Biochemistry       Date:  2000-06-27       Impact factor: 3.162

7.  Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Authors:  Gregory J Aune; Kazutaka Takagi; Olivier Sordet; Josée Guirouilh-Barbat; Smitha Antony; Vilhelm A Bohr; Yves Pommier
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

8.  Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Authors:  Federica Grosso; Robin L Jones; George D Demetri; Ian R Judson; Jean-Yves Blay; Axel Le Cesne; Roberta Sanfilippo; Paola Casieri; Paola Collini; Palma Dileo; Carlo Spreafico; Silvia Stacchiotti; Elena Tamborini; Juan Carlos Tercero; Josè Jimeno; Maurizio D'Incalci; Alessandro Gronchi; Jonathan A Fletcher; Silvana Pilotti; Paolo G Casali
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316

9.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Authors:  Claudia Forni; Mario Minuzzo; Emanuela Virdis; Elena Tamborini; Matteo Simone; Michele Tavecchio; Eugenio Erba; Federica Grosso; Alessandro Gronchi; Pierre Aman; Paolo Casali; Maurizio D'Incalci; Silvana Pilotti; Roberto Mantovani
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

10.  Structural insight into DNA joining: from conserved mechanisms to diverse scaffolds.

Authors:  Adele Williamson; Hanna-Kirsti S Leiros
Journal:  Nucleic Acids Res       Date:  2020-05-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.